LRRK2 and cancer: It has been reported that LRRK2 (leucine-rich repeat kinase 2) plays an adaptive role between cancer and Parkinson’s disease and is defined as a new target molecule for cancer therapy due to its increased kinase activity (Warø and Aasly, 2018; Kim and Jeong, 2020).